ClinicalTrials.gg
CompletedNCT00705536Updated Feb 26, 2019Results posted

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

A Phase 1 interventional study of Humalog and Humulin-R in Diabetes Mellitus, sponsored by Halozyme Therapeutics. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Halozyme Therapeutics · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Insulin Lispro in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus.

Enrollment
16th of 24
26 · median 60
Started
2007
with 5 others
Phase 1
2 of 25
none open now
Registered
12th of 25
by date
Lead sponsor
2 of 25
Halozyme Therapeutics

Among the 25 studies testing Insulin Lispro in Diabetes Mellitus, this one is the 16th largest by enrollment of the 24 interventional ones that give a count, is one of 6 that started in 2007, is one of 2 in phase 1, and was the 12th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 25 studies testing Insulin Lispro in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Insulin Lispro in Diabetes Mellitus, or all of them as a file.
02

Study summary

The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of Humalog (insulin lispro) or Humulin-R (recombinant human insulin) when administered as a single subcutaneous (SC) injection of 20 units (U) with or without coadministration of recombinant human hyaluronidase PH20 (rHuPH20).

The study hypothesizes that the time required to reach maximum insulin concentration (tmax) when insulin is administered with rHuPH20 will be comparable or shorter than the time required without rHuPH20.

03

Conditions studied

  • Diabetes Mellitus

Keywords

  • rHuPH20
  • Hyaluronidase
  • Insulin
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male participants aged 18 to 55 years.
  2. (BMI) 18 to 28 kilograms per meter squared (kg/m\^2) and total body weight >70 kilograms (kg) (154 pounds [lb]).
  3. Willingness and ability to comply with the protocol.
  4. Vital signs within the normal range.
  5. Within 7 days before the first injection, metabolic panel results and complete blood count (CBC) within the laboratory normal reference range.
  6. Fasting plasma glucose within the normal range of 90 to 110 milligrams per deciliter (mg/dL) on the morning of the glucose clamp.
  7. Agreement not to father a child or donate sperm and to use effective during the study and for at least 30 days after study completion.
  8. Willingness and ability to sign an form.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic (to include history of seizures) or allergic disease, or history of hypoglycemic episodes.
  2. Known history of diabetes mellitus.
  3. Prior exposure to any insulin or insulin analogs.
  4. Known allergy to hyaluronidase or any other ingredient in HYLENEX.
  5. Known allergy to bee or vespid venom.
  6. Positive urine drug screen results.
  7. Positive (HIV) 1, HIV 2, , or antibody test result.
  8. Any history or evidence of alcohol or drug abuse.
  9. History or evidence of use of any tobacco- or nicotine-containing product within 6 months of screening, or screening urine nicotine concentration >50 nanograms per milliliter (ng/mL).
  10. Use of prescription or nonprescription drugs within 7 days or 5 half-lives, whichever was shorter, except acetaminophen at doses of less than or equal to 1 gram per day (g/day).
  11. Donation of blood in excess of 500 milliliters (mL) within 56 days before dosing.
  12. Failure to limit alcohol consumption and refrain from exercise within 48 hours before each injection.
  13. Known clinically significant intercurrent illness or other major systemic disease that would unduly risk the participant's safety or interfere with the interpretation of results.
  14. Participation in a study of any drug or device 30 days before enrollment in this study.
  15. Unfitness for the study, in the investigator's opinion.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Active comparator
    Humalog first, then Humalog + rHuPH20

    Humalog first, then Humalog + recombinant human hyaluronidase PH20 (rHuPH20) A single subcutaneous (SC) injection of 20 units (U) Humalog on Day 1 of the study, followed by a single SC injection of 20 U Humalog + 300 U rHuPH20 after a washout period of at least 6 days

    Drug: Humalog · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humalog + rHuPH20 first, then Humalog

    Humalog + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humalog A single subcutaneous (SC) injection of 20 units (U) Humalog + 300 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humalog after a washout period of at least 6 days

    Drug: Humalog · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humulin-R first, then Humulin-R + rHuPH20

    Humulin-R (recombinant human insulin) first, then Humulin-R + recombinant human hyaluronidase PH20 (rHuPH20) A single subcutaneous (SC) injection of 20 units (U) Humulin-R on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R + 240 U rHuPH20 after a washout period of at least 6 days

    Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

  • Active comparator
    Humulin-R + rHuPH20 first, then Humulin-R

    Humulin-R (recombinant human insulin) + recombinant human hyaluronidase PH20 (rHuPH20) first, then Humulin-R A single subcutaneous (SC) injection of 20 units (U) Humulin-R + 240 U rHuPH20 on Day 1 of the study, followed by a single SC injection of 20 U Humulin-R after a washout period of at least 6 days

    Drug: Humulin-R · Drug: Recombinant human hyaluronidase PH20 (rHuPH20)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to Maximum Serum Insulin Concentration (Tmax)

    Time to maximum serum insulin concentration (tmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

  2. Maximum Serum Insulin Concentration (Cmax)

    Maximum serum insulin concentration (Cmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

  3. Area Under the Serum Concentration-Time Curve From Time Zero to the Time Required to Reach Endogenous Plasma Glucose Levels (AUC[0-t'])

    Area under the serum concentration-time curve from time zero to the time required to reach endogenous plasma glucose levels (AUC\[0-t'\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

  4. Area Under the Concentration-Time Curve From Time 0 to Time to Reach Maximum Concentration (Tmax) for Serum Insulin With Recombinant Human Hyaluronidase PH20 (rHuPH20) (AUC[0-tmaxPH20])

    Area under the concentration-time curve from time 0 to time to reach maximum concentration (tmax) for serum insulin (Humalog or Humulin-R) with recombinant human hyaluronidase (rHuPH20) (AUC\[0-tmaxPH20\]) for participants who received Humalog or Humulin-R and with rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment and every 3 min from min 0 through 48 for Stage 1 and, and every 3 min from min 0 through 68 for Stage 2 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 48 minutes postdose during Stage 1, or up to 68 minutes postdose during Stage 2

  5. Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone)

    Relative bioavailability was determined by dividing the baseline-corrected geometric mean of the area under the curve (AUC) for insulin (ins) (Humalog or Humulin-R) with recombinant human hyaluronidase PH20 (rHuPH20) by the baseline-corrected geometric mean of the AUC for insulin alone (AUC\[insulin+rHuPH20\]/AUC\[insulin\]). Bioavailability values for participants who received Humalog or Humulin-R and rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

Secondary outcomes

  1. Time to Maximum Glucose Infusion Rate (tGIR[Max])

    Time to maximal effect for glucose infusion rate (tGIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained every 3 minutes during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

  2. Time to Early Half-Maximal Effect for Glucose Infusion Rate (tGIR[early50%])

    Time to early half-maximal effect for glucose infusion rate (tGIR\[early50%\]) for participants who were randomized to Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

  3. Time to Late Half-Maximal Effect for Glucose Infusion Rate (tGIR[late50%])

    Time to late half-maximal effect for glucose infusion rate (tGIR\[late50%\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period. Because the study was only 360 minutes in duration, there was not sufficient time for regular human insulin to show an effect and therefore tGIR(late50%) could not be calculated for participants receiving Humulin-R alone.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

  4. Maximum Glucose Infusion Rate (GIR[Max])

    Maximum glucose infusion rate (GIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

  5. Area Under the Glucose Infusion Rate Curve From 0 to 60 Minutes After Injection (AUC[GIR{0-60}])

    The area under the curve for the glucose infusion rate from minutes (min) 0 to 60 after injection (AUC\[GIR{0-60}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment and every 3 min from min 0 through 60 during the clamp procedure. Means were calculated using analysis of variance with fixed of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 60 minutes postdose during Stage 1 or Stage 2

  6. Area Under the Glucose Infusion Rate Curve From 0 to 120 Minutes After Injection (AUC[GIR{0-120}])

    The area under the glucose infusion rate curve from minutes 0 to 120 after injection (AUC\[GIR{0-120}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 120 during the clamp. Means were calculated using analysis of variance with fixed effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 120 minutes postdose during Stage 1 or Stage 2

  7. Area Under the Glucose Infusion Rate Curve From 0 to 180 Minutes After Injection (AUC[GIR{0-180}])

    The area under the curve for the glucose infusion rate from minutes (min) 0 to 180 after injection (AUC\[GIR{0-180}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 180 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 180 minutes postdose during Stage 1 or Stage 2

  8. Area Under the Glucose Infusion Rate Curve From 0 to 240 Minutes After Injection (AUC[GIR{0-240}])

    The area the glucose infusion rate curve from minutes (min) 0 to 240 after injection (AUC\[GIR{0-240}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 240 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose up to 240 minutes postdose during Stage 1 or Stage 2

  9. Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}])

    The area under glucose infusion rate curve from minutes (min) 0 to 360 after injection (AUC\[GIR{0-360}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 360 during the clamp. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

    Time frame: Predose and up to 360 minutes postdose during Stage 1 or Stage 2

07

Results

Posted Jul 14, 2014

Participant flow

Start Period 1
Participant flow — Start Period 1
MilestoneStage 1: Humalog First, Then Humalog + rHuPH20Stage 1: Humalog + rHuPH20 First, Then HumalogStage 2: Humulin-R First, Then Humulin-R + rHuPH20Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R
Started6677
Received at least 1 dose of study drug6677
Completed6676
Not completed0001
Withdrew: Withdrawal by subject0001
Washout Period of at Least 6 Days
Participant flow — Washout Period of at Least 6 Days
MilestoneStage 1: Humalog First, Then Humalog + rHuPH20Stage 1: Humalog + rHuPH20 First, Then HumalogStage 2: Humulin-R First, Then Humulin-R + rHuPH20Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R
Started6676
Completed6676
Not completed0000
Start Period 2
Participant flow — Start Period 2
MilestoneStage 1: Humalog First, Then Humalog + rHuPH20Stage 1: Humalog + rHuPH20 First, Then HumalogStage 2: Humulin-R First, Then Humulin-R + rHuPH20Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R
Started6676
Completed6676
Not completed0000
Completed Study
Participant flow — Completed Study
MilestoneStage 1: Humalog First, Then Humalog + rHuPH20Stage 1: Humalog + rHuPH20 First, Then HumalogStage 2: Humulin-R First, Then Humulin-R + rHuPH20Stage 2: Humulin-R + rHuPH20 First, Then Humulin-R
Started6676
Completed6676
Not completed0000

Outcome measures

PrimaryTime to Maximum Serum Insulin Concentration (Tmax)

Time to maximum serum insulin concentration (tmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Minutes
Time to Maximum Serum Insulin Concentration (Tmax)
MinutesStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Time to Maximum Serum Insulin Concentration (Tmax)97.5 ± 35.948.0 ± 7.99163 ± 51.567.8 ± 19.1
Statistical analysis
  • Stage 1: Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = 0.0006 (Treatment comparison of Humalog alone and Humalog + rHuPH20 using a pairwise t-test.)
  • Stage 2: Humulin-R Alone vs Stage 2: Humulin-R + rHuPH20 · ANOVA · p = 0.0002 (Treatment comparison of Humulin-R alone and Humulin-R + rHuPH20 using a pairwise t-test.)
PrimaryMaximum Serum Insulin Concentration (Cmax)

Maximum serum insulin concentration (Cmax) values for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Picomoles per liter
Maximum Serum Insulin Concentration (Cmax)
Picomoles per literStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Maximum Serum Insulin Concentration (Cmax)680 ± 3611290 ± 471390 ± 137944 ± 257
Statistical analysis
  • Stage 1: Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = 0.0003 (Treatment comparison of Humalog alone and Humalog + rHuPH20 using a pairwise t-test.)
  • Stage 2: Humulin-R Alone vs Stage 2: Humulin-R + rHuPH20 · ANOVA · p = <0.0001 (Treatment comparison of Humulin-R alone and Humulin-R + rHuPH20 using a pairwise t-test.)
SecondaryTime to Maximum Glucose Infusion Rate (tGIR[Max])

Time to maximal effect for glucose infusion rate (tGIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained every 3 minutes during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Minutes
Time to Maximum Glucose Infusion Rate (tGIR[Max])
MinutesStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Time to Maximum Glucose Infusion Rate (tGIR[Max])193 ± 58.2114 ± 43.0253 ± 61.8165 ± 51.2
Statistical analysis
  • Stage 1: Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = 0.0059 (Treatment comparison of Humalog alone and Humalog + rHuPH20 using a pairwise t-test.)
  • Stage 2: Humulin-R Alone vs Stage 2: Humulin-R + rHuPH20 · ANOVA · p = 0.0105 (Treatment comparison of Humulin-R alone and Humulin-R + rHuPH20 using a pairwise t-test.)
SecondaryTime to Early Half-Maximal Effect for Glucose Infusion Rate (tGIR[early50%])

Time to early half-maximal effect for glucose infusion rate (tGIR\[early50%\]) for participants who were randomized to Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Minutes
Time to Early Half-Maximal Effect for Glucose Infusion Rate (tGIR[early50%])
MinutesStage 1. Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Time to Early Half-Maximal Effect for Glucose Infusion Rate (tGIR[early50%])72.3 ± 16.643.8 ± 15.1104 ± 33.347.4 ± 13.1
Statistical analysis
  • Stage 1. Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = 0.0002 (Treatment comparison for Humalog alone and Humalog + rHuPH20 using a pairwise t-test.)
  • Stage 2: Humulin-R Alone vs Stage 2: Humulin-R + rHuPH20 · ANOVA · p = <0.0001 (Treatment comparison of Humulin-R alone and Humulin-R + rHuPH20 using a pairwise t-test.)
SecondaryTime to Late Half-Maximal Effect for Glucose Infusion Rate (tGIR[late50%])

Time to late half-maximal effect for glucose infusion rate (tGIR\[late50%\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period. Because the study was only 360 minutes in duration, there was not sufficient time for regular human insulin to show an effect and therefore tGIR(late50%) could not be calculated for participants receiving Humulin-R alone.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Minutes
Time to Late Half-Maximal Effect for Glucose Infusion Rate (tGIR[late50%])
MinutesStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R + rHuPH20
Time to Late Half-Maximal Effect for Glucose Infusion Rate (tGIR[late50%])324 ± 32.9275 ± 48.0282 ± 68.0
Statistical analysis
  • Stage 1: Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = 0.3019 (Treatment comparison for Humalog alone and Humalog + rHuPH20 using a pairwise t-test.)
PrimaryArea Under the Serum Concentration-Time Curve From Time Zero to the Time Required to Reach Endogenous Plasma Glucose Levels (AUC[0-t'])

Area under the serum concentration-time curve from time zero to the time required to reach endogenous plasma glucose levels (AUC\[0-t'\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from 3 milliliter (mL) blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Picomoles per liter times minutes
Area Under the Serum Concentration-Time Curve From Time Zero to the Time Required to Reach Endogenous Plasma Glucose Levels (AUC[0-t'])
Picomoles per liter times minutesStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Area Under the Serum Concentration-Time Curve From Time Zero to the Time Required to Reach Endogenous Plasma Glucose Levels (AUC[0-t'])116000 ± 23000133000 ± 2180091400 ± 25700137000 ± 32800
Statistical analysis
  • Stage 1: Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = 0.0401 (Treatment comparison of Humalog alone and Humalog + rHuPH20 using a pairwise t-test.)
  • Stage 2: Humulin-R Alone vs Stage 2: Humulin-R + rHuPH20 · ANOVA · p = 0.0004 (Treatment comparison of Humulin-R alone and Humulin-R + rHuPH20 using a pairwise t-test.)
PrimaryArea Under the Concentration-Time Curve From Time 0 to Time to Reach Maximum Concentration (Tmax) for Serum Insulin With Recombinant Human Hyaluronidase PH20 (rHuPH20) (AUC[0-tmaxPH20])

Area under the concentration-time curve from time 0 to time to reach maximum concentration (tmax) for serum insulin (Humalog or Humulin-R) with recombinant human hyaluronidase (rHuPH20) (AUC\[0-tmaxPH20\]) for participants who received Humalog or Humulin-R and with rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment and every 3 min from min 0 through 48 for Stage 1 and, and every 3 min from min 0 through 68 for Stage 2 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 48 minutes postdose during Stage 1, or up to 68 minutes postdose during Stage 2
Reported as:
Mean · Picomoles per liter times minutes
Area Under the Concentration-Time Curve From Time 0 to Time to Reach Maximum Concentration (Tmax) for Serum Insulin With Recombinant Human Hyaluronidase PH20 (rHuPH20) (AUC[0-tmaxPH20])
Picomoles per liter times minutesStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Area Under the Concentration-Time Curve From Time 0 to Time to Reach Maximum Concentration (Tmax) for Serum Insulin With Recombinant Human Hyaluronidase PH20 (rHuPH20) (AUC[0-tmaxPH20])9530 ± 1050027900 ± 143008780 ± 301034800 ± 9150
Statistical analysis
  • Stage 1: Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = <0.0001 (Treatment comparison of Humalog alone and Humalog +rHuPH20 using a pairwise t-test.)
  • Stage 2: Humulin-R Alone vs Stage 2: Humulin-R + rHuPH20 · ANOVA · p = <0.0001 (Treatment comparison of Humulin-R alone and Humulin-R + rHuPH20 using a pairwise t-test.)
PrimaryRelative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone)

Relative bioavailability was determined by dividing the baseline-corrected geometric mean of the area under the curve (AUC) for insulin (ins) (Humalog or Humulin-R) with recombinant human hyaluronidase PH20 (rHuPH20) by the baseline-corrected geometric mean of the AUC for insulin alone (AUC\[insulin+rHuPH20\]/AUC\[insulin\]). Bioavailability values for participants who received Humalog or Humulin-R and rHuPH20 were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Ratio of AUC(ins+rHuPH20)/AUC(ins alone)
Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone)
Ratio of AUC(ins+rHuPH20)/AUC(ins alone)Stage 1: Humalog + rHuPH20Stage 2: Humulin-R + rHuPH20
Relative Bioavailability (Area Under the Curve [AUC] for Insulin + Recombinant Human Hyaluronidase [rHuPH20] / AUC for Insulin Alone)1.18 ± 0.2211.57 ± 0.406
SecondaryMaximum Glucose Infusion Rate (GIR[Max])

Maximum glucose infusion rate (GIR\[max\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase PH20 (rHuPH20) were measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 through 360 throughout the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Milligrams per kilogram per minute
Maximum Glucose Infusion Rate (GIR[Max])
Milligrams per kilogram per minuteStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Maximum Glucose Infusion Rate (GIR[Max])8.11 ± 4.488.57 ± 4.247.82 ± 2.5210.5 ± 3.89
Statistical analysis
  • Stage 1: Humalog Alone vs Stage 1: Humalog + rHuPH20 · ANOVA · p = 0.5589 (Treatment comparison of Humalog alone and Humalog + rHuPH20 using a pairwise t-test.)
  • Stage 2: Humulin-R Alone vs Stage 2: Humulin-R + rHuPH20 · ANOVA · p = 0.0067 (Treatment comparison of Humulin-R alone and Humulin-R + rHuPH20 using a pairwise t-test.)
SecondaryArea Under the Glucose Infusion Rate Curve From 0 to 60 Minutes After Injection (AUC[GIR{0-60}])

The area under the curve for the glucose infusion rate from minutes (min) 0 to 60 after injection (AUC\[GIR{0-60}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment and every 3 min from min 0 through 60 during the clamp procedure. Means were calculated using analysis of variance with fixed of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 60 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Grams per kilogram
Area Under the Glucose Infusion Rate Curve From 0 to 60 Minutes After Injection (AUC[GIR{0-60}])
Grams per kilogramStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Area Under the Glucose Infusion Rate Curve From 0 to 60 Minutes After Injection (AUC[GIR{0-60}])82.8 ± 51.9167 ± 81.074.3 ± 40.4180 ± 57.7
SecondaryArea Under the Glucose Infusion Rate Curve From 0 to 120 Minutes After Injection (AUC[GIR{0-120}])

The area under the glucose infusion rate curve from minutes 0 to 120 after injection (AUC\[GIR{0-120}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 minute (min) prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 120 during the clamp. Means were calculated using analysis of variance with fixed effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 120 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Grams per kilogram
Area Under the Glucose Infusion Rate Curve From 0 to 120 Minutes After Injection (AUC[GIR{0-120}])
Grams per kilogramStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin AloneStage 2: Humulin-R + rHuPH20
Area Under the Glucose Infusion Rate Curve From 0 to 120 Minutes After Injection (AUC[GIR{0-120}])393 ± 242597 ± 278281 ± 123637 ± 216
SecondaryArea Under the Glucose Infusion Rate Curve From 0 to 180 Minutes After Injection (AUC[GIR{0-180}])

The area under the curve for the glucose infusion rate from minutes (min) 0 to 180 after injection (AUC\[GIR{0-180}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, and every 15 min from min 60 through 180 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 180 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Grams per kilogram
Area Under the Glucose Infusion Rate Curve From 0 to 180 Minutes After Injection (AUC[GIR{0-180}])
Grams per kilogramStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Area Under the Glucose Infusion Rate Curve From 0 to 180 Minutes After Injection (AUC[GIR{0-180}])801 ± 4201040 ± 501604 ± 2621150 ± 348
SecondaryArea Under the Glucose Infusion Rate Curve From 0 to 240 Minutes After Injection (AUC[GIR{0-240}])

The area the glucose infusion rate curve from minutes (min) 0 to 240 after injection (AUC\[GIR{0-240}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 240 during the clamp procedure. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose up to 240 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Grams per kilogram
Area Under the Glucose Infusion Rate Curve From 0 to 240 Minutes After Injection (AUC[GIR{0-240}])
Grams per kilogramStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Area Under the Glucose Infusion Rate Curve From 0 to 240 Minutes After Injection (AUC[GIR{0-240}])1240 ± 6181430 ± 7061010 ± 4111630 ± 467
SecondaryArea Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}])

The area under glucose infusion rate curve from minutes (min) 0 to 360 after injection (AUC\[GIR{0-360}\]) for participants who received Humalog or Humulin-R with or without recombinant human hyaluronidase (rHuPH20) was measured from blood samples obtained during a euglycemic clamp procedure. Samples were taken 10 and 1 min prior to treatment, every 3 min from min 0 through 60, every 15 min from min 60 through 180, and every 60 min from min 180 to 360 during the clamp. Means were calculated using analysis of variance with effects of participant, sequence within participant, treatment, and period.

Time frame:
Predose and up to 360 minutes postdose during Stage 1 or Stage 2
Reported as:
Mean · Grams per kilogram
Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}])
Grams per kilogramStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Area Under the Glucose Infusion Rate Curve From 0 to 360 Minutes After Injection (AUC[GIR{0-360}])1940 ± 9631930 ± 9881860 ± 6722260 ± 611

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Stage 1: Humalog Alone—0/12 (0%)3/12 (25%)
Stage 1: Humalog + rHuPH20—0/12 (0%)3/12 (25%)
Stage 2: Humulin-R Alone—0/13 (0%)2/13 (15.4%)
Stage 2: Humulin-R + rHuPH20—0/14 (0%)3/14 (21.4%)
Most frequent other events
Most frequent other events
EventStage 1: Humalog AloneStage 1: Humalog + rHuPH20Stage 2: Humulin-R AloneStage 2: Humulin-R + rHuPH20
Infusion site painGeneral disorders1/123/120/131/14
DysgeusiaNervous system disorders1/120/120/130/14
HeadacheNervous system disorders1/120/120/130/14
Pain in extremityMusculoskeletal and connective tissue disorders0/120/121/130/14
Injection site pruritusGeneral disorders0/120/121/130/14
HematomaVascular disorders0/120/121/130/14
Infusion site reactionGeneral disorders0/120/120/131/14
Influenza-like illnessGeneral disorders0/120/120/131/14
Chest discomfortGeneral disorders0/120/120/131/14

Baseline characteristics

All participants who received at least 1 dose of Humalog or Humulin-R with or without rHuPH20.

Age, Continuous
Age, Continuous(years)Stage 1: Humalog Alone or Humalog + rHuPH20Stage 2: Humulin-R Alone or Humulin-R + rHuPH20Total
Mean37.7 ± 7.836.7 ± 8.937.2 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Stage 1: Humalog Alone or Humalog + rHuPH20Stage 2: Humulin-R Alone or Humulin-R + rHuPH20Total
Female000
Male121426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Stage 1: Humalog Alone or Humalog + rHuPH20Stage 2: Humulin-R Alone or Humulin-R + rHuPH20Total
Hispanic or Latino91019
Not Hispanic or Latino347
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Stage 1: Humalog Alone or Humalog + rHuPH20Stage 2: Humulin-R Alone or Humulin-R + rHuPH20Total
American Indian or Alaska Native303
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American235
White71118
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Stage 1: Humalog Alone or Humalog + rHuPH20Stage 2: Humulin-R Alone or Humulin-R + rHuPH20Total
United States121426
08

Study locations

1 site
  • Diabetes and Glandular Disease Research, Inc.
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther. 2009 Jun;11(6):345-52. doi: 10.1089/dia.2009.0013. PubMed 19459762 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 6 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2008
First posted
Jun 26, 2008
Start
Dec 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Jul 14, 2014
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00705536
Responsible party
Sponsor
First posted
Jun 26, 2008
Start date
Dec 2007
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Jul 14, 2014
Last update
Feb 26, 2019

Study contacts

Mark S. Kipnes, MD
principal investigator · Diabetes and Glandular Disease Research Associates Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Insulin, Regular, Human

Start the discussion